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ABSTRACT 
Cytotoxic effector cells can target and kill parenchymal cells of the kidney which results in 
injury and loss of function. Endogenous regulatory systems may exist to attenuate Natural 
Killer (NK) and other effector cell activation and cytotoxicity in diverse conditions, including 
ischemia-reperfusion injury associated with kidney transplantation. Understanding these 
mechanisms will direct new therapeutic strategies. Kidney tubular epithelial cells (TEC), the 
predominant cell type in kidneys, may negatively regulate NK cell activation by surface 
expression of C-type lectin-related proteins (Clr). Clr-b and -f were found to be expressed by 
wild type (WT) TEC. Clr-b was upregulated by TNFα+IFNγ in vitro. Elimination of both Clr-
b and Clr-f expression with siRNA resulted in increased NK killing of TEC compared to 
individual silencing of Clr-b or Clr-f TEC (p<0.01), or WT control TEC (p<0.001). NK cells 
treated in vitro with soluble Clr-b and Clr-f reduced their capacity to kill Clr-b/-f -/- TEC as 
compared to untreated NK cells (p<0.05). NK cells therefore are regulated by proteins 
expressed by TEC and thus may represent an important endogenous regulatory system in the 
kidney to limit organ injury. As no current drugs exist to specifically target NK cells, Clr-b 
and Clr-f soluble proteins that bind to NK cells may represent a novel and clinically feasible 
strategy to protect organs from NK cell-mediated inflammation during ischemia-reperfusion 
and other kidney injury models. 
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Chapter 1  
1 INTRODUCTION 
 
1.1 Challenges in Kidney Transplantation 
Chronic Kidney Disease (CKD) has been increasingly recognized as a global health 
problem (1). It has been noted that patients suffering from CKD are also likely to develop 
hypertension, and cardiovascular disease with increased mortality (2). In the early stages 
of CKD, kidney function can be maintained or sometimes improved by commitment to 
improved diet and medications to control fluid accumulation, blood sugar in diabetes, 
calcium/phosphate levels, anemia, and blood pressure (3). However, once kidney function 
decreases to less than 10-15% of normal levels, End Stage Renal Disease (ESRD) exists 
with increased complications from hypertension, malnutrition, bone disease, and ultimately 
death without treatment (4). Currently, there are two viable treatment options for ESRD: 
dialysis and kidney transplantation (5). Many studies have indicated that kidney 
transplantation is associated with decreased mortality and an increased quality of life in 
comparison to chronic dialysis treatment in selected patients (5, 6). While highly variable 
depending on other morbidities, kidney transplant patients can gain 10 to 15 years of life 
compared to those remaining on dialysis (6). Despite the many benefits of renal 
transplantation, complications can arise after the procedure that lead to acute rejection or 
the greatest current challenge: the development of chronic allograft injury. This complex, 
multifactorial entity is poorly understood and has no defined therapy. 
Nonimmunological (antigen-independent) factors that affect the success of a renal 
transplant include organ viability, drug toxicity, and recipient factors (7). The viability of 
a donor organ can be affected by many factors including age, prolonged cold ischemic 
time, donor brain injury, renal mass, delayed graft function, acute tubular necrosis, and 
whether the donor was living or deceased (7). Additionally, if the transplant recipient has 
a lipid disorder, diabetes, hypertension, or any kind of circulatory obstructions, the success 
of the graft may be shortened (7). The immunological (antigen-dependent) factors that can 
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promote allograft injury are related to antibody (humoral) and cellular immunity, as well 
as infection (7). Graft injury complications can arise from antibody-mediated rejection 
(ABMR), particularly if the recipient has been previously sensitized to donor antigens (7). 
Similarly, cellular immunity arising from direct or indirect allorecognition is influenced by 
prior antigen exposure, or by failure of immunosuppression to adequately subdue the 
recipient’s immune responses (7). Lastly, despite immunosuppression being a critical 
element of a successful transplantation, unintended side effects of conventional 
immunosuppressants can create the opportunity for viral and other infections, particularly 
by human cytomegalovirus and BK (Bren nan-Krohn) polyomavirus (7). 
The primary challenge in kidney transplantation remains to be allograft rejection 
mediated by the alloimmune response (8). This alloimmune response is multifaceted, and 
a complete understanding of its many components is required to guide research towards 
effective therapies. The principle targets of the immune response to allogeneic tissues are 
highly polymorphic major histocompatibility complex (MHC) molecules or human 
leukocyte antigens (HLA) as they are termed in humans (9). HLA matching between donor 
and recipient significantly reduces the risk of graft rejection and failure following solid 
organ transplantation (9). The alloimmune response involves components of both the 
innate and adaptive immune system, which are linked during inflammation. In both the 
graft and surrounding tissues, donor and recipient dendritic cells (DCs) become activated 
by inflammation and innate responses, and migrate into secondary lymphoid organs to 
present alloantigens to T cells with cognate T cell receptors (10). This interaction activates 
signal transduction pathways that trigger increased CD4+ T helper cell expression of 
molecules like the growth factor Interleukin-2 (IL-2) and its high affinity receptor CD25, 
resulting in proliferation of CD8+ effector T cells, and other cells (11, 12). Additionally, B 
cells are activated to generate alloantibodies against donor HLA and non-HLA antigens 
(10, 13, 14). In a matter of days, a robust alloimmune response consisting of alloantibodies 
and effector T cells can be initiated against the donor organ. A rare and more rapid form of 
rejection, termed Hyperacute Rejection, can occur if the recipient possesses unrecognized 
or undetected pre-formed antibodies against blood group or HLA antigens (15). This pre-
sensitization can be facilitated by events such as pregnancy, a prior blood transfusion, or a 
previous transplant (16). Recipients with previous exposure to donor antigens also have 
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high affinity alloreactive memory T cells that represent an essential element of allograft 
rejection and a major barrier to tolerance induction in transplantation (17–20).  Memory 
CD4+ T cells are resistant to current immunosuppressive therapies and can provide help in 
the generation of donor specific antibodies leading to alloantibody-mediated graft injury 
(21, 22). Direct contact of circulating memory CD8+ T cells with donor tissue can trigger 
reaction to donor MHC class-1, proliferation, and expression of IFNγ (23–26). As long-
term kidney transplant survival has not appreciably increased over the past 20 years, it is 
intuitive that with so many components of the immune system contributing to allograft 
injury, new insights and knowledge are required to generate new strategies that can be 
translated into the clinic before we will achieve improved transplant outcomes.  
 
1.2 Acute Allograft Injury and Ischemia Reperfusion Injury 
Transplantation is invariably associated with some degree of acute allograft injury 
initially caused by ischemia reperfusion injury (IRI) (27). Kidney IRI (K-IRI) is a 
prominent cause of delayed graft function and under severe circumstances can lead to early 
graft loss via acute renal failure (ARF) (28). Ischemia occurs in the early stages of the 
surgical procedure when blood vessels in the recipient are clamped, removing oxygenated 
blood supply to the tissue, and thus creating a hypoxic and nutrient deficient environment 
(29). Reperfusion injury is the result of restoring blood flow to the resident tissue, and upon 
reintroduction with oxygen, reactive oxygen species (ROS) are formed (29). Free radical 
mediated oxidative stress causes an upregulation of pro-inflammatory cytokines and 
chemokines (30). Chemokines from the CC, CXC, and CX3C chemokines families are 
early mediators of inflammation in renal IRI (31, 32). These chemokines help to increase 
vascular permeability and expression of endothelial cell adhesion molecules that mediate 
leukocyte infiltration and activation (33, 34). Additionally, damage to host cells caused by 
oxidative stress can trigger activation of both the toll-like receptor (TLR) and Complement 
arms of the innate immune system (30). Endogenous ligands such as high-mobility box 
group 1 (HMGB1) released by damaged cells during K-IRI function as ligands for TLR4 
receptors (35). Activation of the Complement system can be mediated through the impaired 
expression of complement regulatory proteins on the surface of tubular epithelial cells 
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(TEC) (36, 37). Both the Complement system and engagement of TLR4 can induce TEC 
to produce pro-inflammatory chemokines, macrophage inflammatory protein 2 (MIP-2), 
and cytokines IL-6 and TNF-, augmenting immune responses (30).  
A histological hallmark of IRI is neutrophil and macrophage infiltration into the 
graft (38–40). Neutrophils are potent effector cells which cause injury by obstructing renal 
microvasculature and releasing ROS and proteases. Macrophages secrete cytokines like 
IFN-, recruit neutrophils, and induce programmed cell death of resident tissue cells (40). 
While the role of NK cells in IRI has not been well defined, a study conducted by Zhang 
et al. has demonstrated the key role of NK cells in acute and chronic allograft kidney injury 
(41–43). NK cells can directly kill TEC following IRI, and adoptive transfer of NK cells 
into mice lacking all lymphoid immune cells worsened injury after IRI (41). It has become 
evident that the adaptive immune system also participates in K-IRI, with crucial 
contributions originating from CD4+ T cells. CD4+ T cells infiltrate the graft within 4 hours 
following ischemia but resolve after 24 hours in what has been termed as a “hit-and-run” 
phenomenon (38, 39, 44). In addition to T cells being recruited early following IRI, resident 
dendritic cells, CD19+ B cells, CD3- NK1.1+ NK cells, and CD4+ NK1.1+ NKT cells also 
infiltrate the kidney (39). These cells can further progress inflammation, IRI, and acute 
allograft injury.  
TEC comprise more than 75% of renal parenchymal cells, and their susceptibility 
to acute injury contributes to the success or failure of kidney transplants, as tubular injury 
can be a primary cause of nephron loss (45). Basically, eventual graft failure can occur if 
TEC cell death exceeds the kidney’s regenerative capacity. TEC located in the proximal 
tubules of the cortex are particularly sensitive to IRI (4, 37–39). Proximal TEC are 
responsible for reabsorption of solutes and water back into the bloodstream, and loss or 
disruption of these cells can lead to organ dysfunction (49). In acute renal allograft 
rejection, perforin and granzyme B lytic pathways as well as Fas-FasL interactions mediate 
TEC death (50). Several studies have identified that perforin and granzyme B pathways 
participate in CD56+ NK and CD3+ cytotoxic lymphocyte-mediated destruction of tubular 
cells (51–53). In addition, FasL, expressed by TEC, interacts with Fas to initiate apoptosis 
of immune cells (54, 55) as well as adjacent TEC, termed “fratricide” (56, 57). 
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Understanding the extent by which TEC influence the severity of IRI is crucial in 
developing therapeutic options to reduce acute kidney injury.  
 
1.3 Preventing acute injury and chronic graft rejection 
In the modern era, rates of acute allograft rejection have been reduced by the 
application of potent immunosuppressive drugs. Immunosuppressive drugs are utilized 
either to deplete lymphocytes, divert lymphocyte traffic, or block lymphocyte activation 
pathways (10). A combination of T and B cell depleting antibodies, calcineurin inhibitors 
(CNI) such as tacrolimus, anti-proliferative agents such as azathioprine, mTOR inhibitors 
such as sirolimus, and glucocorticoids are used in various combinations to suppress the 
recipient’s immune responses (10). Despite these drugs, chronic allograft dysfunction 
remains the leading cause of late kidney graft loss (58). Chronic allograft injury which was 
previously termed chronic allograft nephropathy (CAN), is characterized by progressive 
tubular atrophy, interstitial fibrosis, and damage to the microvascular and glomeruli (7, 
59). Chronic graft rejection as a result of CAN and other associated injuries typically occurs 
5 to 10 years after transplantation with a slow decay in graft function (59). The incidence 
of CAN in transplant patients is as high as 60% of grafts 10 years post-transplant (60). 
Currently, no specific strategies have been implemented to combat the progression and 
incidence of chronic allograft injury or fibrosis. Chronic allograft injury is generally 
irreversible (59), and if kidney failure and subsequent graft loss should occur, the patient 
must either return to dialysis or receive another transplant.  
To effectively develop drug strategies to combat chronic allograft rejection, an 
understanding of how acute injury events such as IRI might contribute to chronic injury or 
identifying effector cells that are not affected by current drugs is clearly essential. NK cells 
can directly lyse TECs and are capable of initiating and contributing to K-IRI in the absence 
of B and T cells (41, 61). Recent studies have demonstrated that NK can trigger chronic 
allograft vasculopathy, as well as enhance both T cell and antibody-mediated chronic 
cardiac allograft rejection (43, 62). Though current immunosuppression may influence 
recipient NK cell cytokine production and phenotype, it is insufficient to alter their 
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cytotoxic capacity (63). A study by Hoffmann et al. demonstrated that, IFN- production 
of NK cells of kidney transplant patients was retained after stimulation with 
PMA/Ionomycin, and coculture with HLA-class-1 deficient K562 human myelogenous 
leukemia cells (64). Additionally, degranulation and release of perforin and granzyme A/B 
was not impaired in kidney transplant recipients compared to healthy individuals (64).  
 
1.4 NK cell Biology and Function 
 NK cells are bone marrow-derived innate lymphoid cells that develop from a 
common lymphoid progenitor cell capable of giving rise to all lymphocyte subsets (65). 
NK cells attempt to induce cytotoxicity in abnormal or foreign cells through the release of 
perforin and granzyme, and contribute to a full inflammatory immune response by 
releasing cytokines such as IFN-, TNF-, and granulocyte-macrophage colony 
stimulating factor (GM-CSF) (66–68). NK cells express an array Type II integral 
membrane proteins with C-type lectin extracellular domains encoded by the Natural Killer 
Gene Complex (NKC) (69). These proteins act as receptors that interact with ligands on 
target cells, resulting either in the stimulation or inhibition of NK cell activity (69).  NK 
cell activation occurs in the absence of inhibition by the binding of MHC class-1 to the 
inhibitory members of the murine Ly49 receptor family or their human analogues, the killer 
cell immunoglobulin-like receptors (KIRs). NK cell activation triggered by the absence of 
MHC class-1 binding to these inhibitory receptors has been termed the “Missing-self 
Hypothesis” (70). Absence of MHC class-1 is particularly relevant in initiating an immune 
response against viral infections and cancer, as pathologically transformed and virus-
infected cells often downregulate class-1 MHC in an attempt to escape discovery by cells 
of the adaptive immune system (71, 72). A second method of NK cell activation is termed 
“Target Interference” where stimulatory signals are present while the major inhibitory 
signal from MHC class-1 is absent (70). Activation is triggered by stimulatory NK cell 
receptors (NKCs) such as NKp30, NKp44, and NKp46 that in the presence of MHC class-
1 that would not normally be sufficient to cause activation (70). A third means of NK cell 
activation is termed “Induced Self” which arises when inhibitory signals are outcompeted 
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by signals from the activating receptor NKG2D (70). The NKG2D receptor present on NK 
cells interacts with stimulatory ligands Rae-1. MULT-1, and H60 in mice and ULBP and 
MICA/B in humans (70).  
 The role NK cells play in solid organ transplantation is of particular interest due to 
their constitutive and  potent cytotoxicity, with a capacity to lyse target cells in the absence 
of pre-sensitization, as well as ability to distinguish between allogeneic MHC antigens 
(73). In addition to their direct cytotoxic activity, NK cells produce and release IFN- and 
TNF- to stimulate a robust innate immune response (74, 75). It has been demonstrated 
that NK cells infiltrate kidney grafts after ischemia and participate in K-IRI by lysing TEC 
directly in a perforin-dependent manner (41, 61). NK cells can thus affect transplant 
outcomes due to their ability to promote alloreactivity responses of T cells as well as by 
killing antigen presenting cells that might contribute to tolerance (76). Finally, Hirohashi 
et al. demonstrated that NK cells play a necessary role in the development of antibody-
mediated chronic rejection in an Fc-dependent and complement-independent manner (62). 
Evidently, NK cells have a significant effect on transplantation outcomes, and the 
mechanisms regulating NK function in the kidney should be clarified.  
While donor-recipient HLA/MHC matching is important to prevent rejection 
mediated in-part by NK cells, it is clear that there are many other receptors expressed on 
the surface of parenchymal cells that can regulate NK cell activation. Within the past 20 
years, a complex network of regulatory interactions that exist between NK cells and their 
targets has become more defined. Central to this regulation appears to be members of the 
NK receptor NKR-P1 family in mice and KLRB1 family in humans, which interact with 
C-type lectin-related proteins (Clrs) encoded by the Clec2 genes on target cells (77–79). 
Clrs are glycosylated disulfide-linked homodimeric type II transmembrane proteins 
expressed on the surface of a wide variety of cell types across different tissues and species 
(78). Several different NKR-P1:Clr interactions have been identified to either promote the 
stimulation or inhibition of NK cell cytotoxic activity (79).  
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1.5 Clr Ligands and NKR-P1 Receptors 
Like the major histocompatibility complex genes, the genes encoding the natural 
killer cell receptors possess significant interspecies genomic diversity (80, 81). The Ly49 
and KIR innate pattern recognition systems are highly polymorphic and polygenic. The 
C57BL/6 mouse strain possesses a Ly49 genomic cluster that encodes two functional 
stimulatory Ly49 receptors (Ly49d, h) and eight functional inhibitory receptors (Ly49a, c, 
e, f, g, i, j, q) (81).  On the other hand, the structurally and functional related Nkrp1 gene 
family possesses a highly conserved genomic organization within individual murine 
strains. This lack of diversity suggests a resistance to evolutionary diversification (81). 
The NK1.1 alloantigen has long been used as marker for NK cell identification and 
purification (82, 83). Subsequently, the NK1.1 alloantigen was revealed to be a member of 
the NKR-P1 family of receptors in mice and shown to possess the capacity to produce an 
activation signal in NK cells (84–87). To date, the Nkrp1a, -b, -c, d-, -e, -f, and –g genes 
have been identified to code for their corresponding NKR-P1 receptor isoform, though 
studies have suggested that the Nkrp1-e is non-functional (79). It has been predicted that 
NKR-P1A, NKR-P1-C, and NKR-P1F receptors exert stimulatory effects on NK cells, 
while activation of NKR-P1B, NKR-P1D, and NKR-P1G cause inhibitory effects (77, 88–
90). In 2001, Plougastel et al. identified a novel set of Clr genes that were subsequently 
named Clr-a, -b, -c, d-, -e, -f, and –g, where Clr-b was identical to the osteoclast inhibitory 
ligand (Ocil) and many others were similar to members of the Ocil gene family (91, 92).  
Several screening studies in mice have identified ligands for different NKR-P1 
receptors discovered an interaction between the NKR-P1 family members and the Clr 
proteins (81). These are very complex interactions. Despite the fact that many 
physiological functions of Clrs have yet to be discovered, the known mouse receptor:ligand 
interactions are NKR-P1B/D:Clr-b, NKR-P1F:Clr-c, -d, and –g, and NKR-P1G:Clr-d, -f, -
g (79). In humans, NKR-P1A (KLRB1/CD161) expressed on NK cells shows inhibitory 
function upon binding the Clr-related ligand LLT1 (93, 94). Stimulatory cross linking of 
NKR-P1 receptors like NKR-P1A, -C, and –F results in phosphorylation of the FcRγ 
immunoreceptor tyrosine-based activation motif (ITAM) tyrosine residues (88). This 
recruits spleen tyrosine kinases (Syk) and lymphocyte-specific protein tyrosine kinases 
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(lck), leading activation of NK cytotoxicity through downstream signalling cascades like 
the NF-κB, NFAT, and MAPK pathways (88). In contrast, the inhibitory receptors NKR-
P1B, –D, and -G possess a conserved cytoplasmic immunoreceptor tyrosine-based 
inhibitory motif (ITIM) domain (62, 67). These inhibitory receptors bind Src homology 2 
(SH2)-containing protein tyrosine phosphatase-1 (SHP-1) in a phosphorylation-dependent 
manner, which block downstream signalling cascade activation by inhibiting Syks (77, 89, 
96).  
 
1.6 Immuno-regulatory Role of Clr:NKR-P1 System 
The different Clr proteins are expressed in a tissue- and organ-restricted manner 
(97). In the kidney, it has been identified that “inhibitory” Clrs –b and –f are strongly 
expressed, and “stimulatory” Clrs –c and –g are weakly expressed across different species 
of mice (97). The broad expression of Clr-b across many tissues and hematopoietic cells, 
and its inhibitory interaction with NKR-P1B/D has led to the hypothesis that the NKR-
P1B/D:Clr-b system may act as a second “Missing-self” mechanism. Like Ly49, NKR-
P1B is expressed on approximately 60% of B6 mouse NK cells (97). There is even some 
evidence to suggest that B6 mouse kidneys may contain resident CD11b+ dendritic cells 
that express NKRP1B/D (97). In support of the missing-self-like hypothesis, similar to 
MHC class-1, Clr-b expression is reduced in many tumor cell lines and downregulated in 
response to genotoxic stress and viral infection (98–101). One study demonstrated a 
dominant effect of MHC class-1-dependent NK cell inhibition over the inhibition mediated 
by the NKR-P1B:Clr-b interaction (102). However, it was also demonstrated that 
hematopoietic cells lacking both MHC class-1 and Clr-b were subjected to enhanced 
rejection compared to MHC class-1 deficient or Clr-b deficient cells alone (102).  
Clr-f has been identified via RT-PCR to be expressed very highly by both the 
intestinal epithelium and kidney TEC (97). Across B6, BALB/c, and 129S6 mouse strains, 
Clr-f and NKR-P1G amino acid sequences are highly conserved with a minimum of 99% 
homology (97). A study was conducted by Leibelt et al. that investigated the functional 
consequences of NKR-P1G ligation with Clr-f (103). It was observed that NKR-P1G+ 
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intestinal intraepithelial lymphocytes (IELs) readily degranulate when co-cultured with 
CHO cells, while no degranulation was detected by the same IELs when co-cultured with 
CHO cells ectopically expressing Clr-f (103). Degranulation towards Clr-f + CHO cells was 
restored in the presence of anti-Clr-f blocking mAb 10A8, providing further evidence that 
ligation of NKR-P1G with Clr-f promotes cytotoxic inhibition (103). It is hypothesized that 
IELs utilize the NKR-P1G:Clr-f system to survey the state of intestinal epithelial cells, and 
downregulation of Clr-f may indicate cellular stress, pathogenic challenge, or mucosal 
injury and stimulate a proinflammatory immune response (103). The constitutive 
expression of Clr-f by the kidney suggests it may be an important immune modulator for 
TEC. 
NK cells are efficient cytotoxic effectors which are not targeted by current drug 
strategies in transplantation. Greater insight into the ability of proteins expressed by TEC 
to regulate NK cells may generate effective therapies for acute and chronic kidney injury.  
 
1.7 Hypothesis 
Studies of Clr-b and Clr-f have demonstrated the capacity to engage receptors of 
the NKR-P1 family and play a protective role by attenuating cytotoxic response by innate 
lymphoid effector cells. As both ligands are expressed by TEC, expression of Clrs by 
kidneys and perhaps other organs may represent a potent and complex endogenous 
regulatory mechanism that protects organs from diverse forms of NK-mediated 
inflammation and cytotoxicity. We therefore tested the capacity of inhibitory Clr family 
member expression in regulating TEC susceptibility to NK killing. We hypothesize that 
the endogenous Clrs expressed by TEC play a critical role in regulating NK cell 
cytotoxicity. We tested whether the cytotoxic potency of mature NK cells could be 
attenuated in the presence of TECs expressing Clr-b and –f, as compared to TEC that either 
express low levels of these Clrs or lack them entirely. By manipulating the cellular 
expression of Clr-b and Clr-f, or exposing NK cells to soluble versions of these proteins, 
we believe we can alter the NK cell cytotoxic response against TEC and in K-IRI. 
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Chapter 2  
2 MATERIALS AND METHODS 
 
2.1 Mice 
Wild-type (WT) C57BL/6 (B6; H-2b) mice were purchased from the Charles River Canada 
Inc (St. Constant, QC). The B6 Clr-b-/- (Ocil-/-) mice were generously provided by Dr. 
Matthew Gillespie (Monash University, Clayton, Australia). All animals were maintained 
in the animal facility at Western University using approved protocols and procedures.  
2.2 Tubular Epithelial Cell (TEC) Culture 
TEC were isolated from mouse kidneys after digestion with collagenase (Sigma-Aldrich, 
Oakville, ON, Canada) for 30 min. Enriched TEC were grown on 0.1% collagen-coated 
plates (Sigma Aldrich) in complete K1 culture medium (Life Technologies, Burlington, 
ON, Canada), supplemented with 5% bovine calf serum, hormone mix (5µg/mL of insulin, 
1.25ng/mL of prostaglandin E1 (PGE1), 34 pg/mL of triiodothyronine, 5µg/mL of 
transferrin, 1.73 ng/mL of sodium selenite, and 18ng/mL of hydrocortisone), 25ng/mL of 
EGF. 100 U/mL penicillin and 100µg/mL streptomycin (Life Technologies). Proximal 
tubular phenotype of TEC was confirmed by morphology and flow cytometry through 
staining with anti-CD13, CD26, Cytokeratine, and E-cadherin antibodies. Cells were 
passaged a maximum of two times with 0.25% trypsin (Life Technologies). 
2.3 NK Cell Culture 
NK cells were purified from the spleens of WT and Clr-b-/- C57BL/6 mice. Spleens were 
mechanically processed through a 40 µm cell strainer (BD Biosciences, Mississauga, ON, 
Canada), and whole splenocytes were labelled with anti-CD3ε magnetic MACS beads 
(Miltenyi Biotec, Auburn, CA) for 15 min at 4°C in 300µL of MACS buffer (PBS, 1% 
FBS, 0.5% EDTA). Splenocytes were passed through a magnetic MACS bead column to 
deplete CD3ε+ cells, and the column was washed three times with MACS Buffer. NK cells 
were then purified from the flow through by CD49b+ selection on MACS beads column 
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using anti-CD49b magnetic MACS beads (DX5; Miltenyi). NK cells were primed for 7 
days in the presence of human IL-2 (Proleukin®, Novartis, QC, Canada) (Day1 - 2000 
IU/mL, Day 3 – 1500 IU/mL) in RPMI 1640 supplemented with 10% FCS, 100 U/mL 
penicillin, 100µg/mL streptomycin, 2mM glutamine, 1mM sodium pyruvate, 10mM 
HEPES, and 0.5mM 2-ME. Purity of NK cells was confirmed to be >90% CD49b+ NK1.1+, 
CD3-.  
2.4 Real-Time Quantitative Polymerase Chain Reaction 
Total RNA was extracted from tissue or cells using TRIzol reagent or a PureLinkTM RNA 
Mini Kit (Invitrogen, USA). Concentration and purity of the isolated RNA was determined 
using a GENESYS™ 10S UV-vis spectrophotometer (Thermofisher, Mississauga, ON, 
Canada). Standardized quantities of cDNA were generated from RNA using Superscript II 
(Thermofisher, USA). Real-time quantitative PCR was performed using the Brilliant 
SYBR Green QPCR Master Mix kit (ABM, Vancouver, BC, Canada) and the CFX Connect 
(BioRad, Hercules, CA, USA) on cDNA. Primers are: β-actin F (CCA GCC TTC CTT 
CCT GGG TA), β-actin R (CTA GAA CAT TTG CGG TGCA), Clr-f F (GAA TAT AGC 
AAC TTG GTT CTC) Clr-f R (GGA TTT ACA ACT ACT GAC AAA C), Clr-b F (AGC 
TCC TCA GCT CTG AGA TGT GTG) Clr-b R (AGG GGA GAT GGT TTC CGT GCC 
TTT). β-actin amplification was used as the endogenous control. The normalized δ 
threshold cycle values and relative expression levels (2∆∆Ct) were calculated. 
2.5 OCIL (Clr-b) Mouse Genotype Confirmation 
One cubic millimeter of liver tissue from both WT and Clr-b-/- B6 mice was homogenized 
in TRIzol reagent (Invitrogen, USA). Total RNA was isolated from the tissue, RNA 
concentration and purity was determined, and 5µg of RNA was used to synthesize cDNA 
as described above. PCR was performed on the generated cDNA using the following 
primers: OCIL F (exon2) (TAG TCC CAC AGG CAG CCC GC), OCIL R (exon4) (TGA 
CGA CTC TCT GTG CAG GCC A). The following PCR protocol was used: initial 
denaturation (94˚C for 5 min); 35 cycles (94˚C for 30s, 60˚C for 30s, 72˚C for 45s); final 
extension (72˚C for 4 min). Gel electrophoresis of PCR products was performed on a 1% 
agarose gel with 10µL of SYBR Safe stain (Life Technologies) added. 
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2.6 SiRNA Silencing 
Expression of Clr-b/-f was confirmed in WT and Clr-b-/- TEC using RT-PCR. Primary WT 
and Clr-b-/- B6 TEC were grown to 80% confluency and transfected in vitro with Clr-f 
siRNA targeting exon 5 (ThermoFisher, siRNA ID 85821) using Endofectin™ Max 
Reagent (Genecopoeia, Rockville, MD, USA). Successful silencing was confirmed at 24, 
48, and 72 hrs by RT-PCR. Cells were harvested by trypsin at 48 hrs for use in in vitro 
cytotoxicity assays.  
2.7 51Chromium Release Assay 
Target cell death was measured in NK:TEC co-cultures using a standard 51Chromium 
(51Cr) Release Assay. Briefly, untreated or silenced TEC were labelled with [75µCi] 51Cr 
at 37°C for 1.5 hrs, washed, and then used as targets. IL-2 activated NK cells were prepared 
and used at indicated effector:target ratios against 51Cr-labelled TEC targets seeded at 104 
cell/well of a V-bottom microplate in RPMI 1640 supplemented media. In some 
experiments, 250ng/mL of soluble hGAD65, 80ng/mL of sClr-b, 80ng/mL of sClr-f, or 
80ng/mL of both sClrs was added to wells containing only NK cells thirty minutes prior to 
co-culture. Following 4 hrs of co-culture at 37°C, the plates were spun down for 5 min at 
1500 rpm and 100µL of supernatant was harvested from each well. The release of target 
cell 51Cr was determined in counts per minute (cpm) by a γ counter. The following formula 
was used to calculate specific percent cell death of target cells: % Cell Death = [(ER - 
SR)/(TR – SR)] x 100, where ER (experimental release) is the cpm from wells containing 
both effector and target cells, SR (spontaneous release) from wells containing targets and 
culture media, and TR (total release) from wells containing targets and 1% Triton X-100 
non-ionic surfactant (Sigma Aldrich).   
2.8 Western Blot  
Following protein purification, the soluble proteins were loaded into a 10% SDS-PAGE 
Gel (30% Acrylamide, Gel buffer 1.5 ph8.8, 10% SDS, 10% APS, TEMED) and 
electrophoresis was performed. After electrophoresis, the glass plates were removed from 
the electrophoresis apparatus, and the gel was incubated in cold Transfer Buffer (10% 
methanol, 24nM Tris, 194 mM glycine) for 10 minutes to remove detergent. A Bio-Ice 
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Cooling Unit (Bio-Rad, USA) was filled with water and chilled to -20˚C prior to use. The 
gel, membrane, filter paper, and fiber pads were soaked for 15 minutes in transfer buffer 
and stacked in the transfer cassette. The cassette was placed inside the cooling unit that 
was then filled with transfer buffer. A standard stir bar was added to help maintain even 
buffer temperature and ion distribution in the cooling unit. The transfer was run for 1.5 hrs 
at 80V. After the transfer, the membrane was removed and blocked with 5% non-fat dried 
milk in PBS for 1 hr or overnight at 4˚C on a standard analogue shaker (VWR, Mississauga, 
ON, Canada).  
The membrane was washed (PBS, 0.1% Tween) three times for 10 minutes each on 
the shaker. The membrane was then incubated with rabbit anti-6X His tag antibody 
(Abcam, ab137839, Toronto, ON, Canada) in 2.5% non-fat dried milk in PBS for 1 hr at 
room temperature while shaking. The membrane was washed in the same washing solution 
three times for 10 minutes each. The membrane was then incubated with the secondary 
Goat anti-Rabbit HRP antibody (Seracare, Milford, MA, USA) at 1:5000 dilution for 1 hr 
at room temperature while shaking. The membrane was washed three final times with wash 
buffer, and was developed to allow for protein visualization with a FluorChem M Imaging 
System (ProteinSimple, Sane Jose, CA, USA) 
2.9 NK Cell Viability Assay 
NK cells cultured with IL-2 for 7 days were collected, spun down, re-suspended in RPMI, 
and 300,000 cells/well were pipetted into wells of a 96-well plate. The final volume of each 
well was raised to 200µL with RPMI. Soluble Clr proteins (sClr-f, sClr-b) were added into 
each well at the desired concentrations. Soluble human GAD65 (hGAD65) was created 
using the same plant protein expression and purification method, and was used as an 
irrelevant plant protein control. NK cells were co-cultured with these soluble proteins for 
4 hrs before plates were spun down at 1500 RPM 4˚C. The supernatant was removed, and 
cells were re-suspended in 150µL of Flow Buffer (PBS, 2% FBS, 0.001% NaN3) and 1µL 
of Propidium Iodide (PI) (BD Pharmingen™, Canada) to stain for loss of plasma membrane 
integrity. A Cytoflex S (Beckman Coulter, Mississauga, ON, Canada) flow cytometer was 
used to quantify cell death as defined by PI+ cells. 
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 NK cell viability was also measured kinetically using an IncuCyte Live-Cell 
Analysis System (Essen Bioscience Inc, Ann Arbor, MI, USA). Cells were added to a 96-
well plate and cultured with sClr and hGAD65 as described above. Each well also 
contained 100 nM of Sytox Green Nucleic Acid Stain (Thermofisher) that is impermeant 
to live cells. The 96-well plate was placed inside a tray in the IncuCyte, and fluorescent 
images of each well was taken periodically at a 4x magnification. The IncuCyte software 
was used to count the total number of cells, and the number of green Sytox positive cells 
in each well. The following formula was used to calculate specific percent cell death of 
NK cells in each well: % Cell Death = [(ER - SR)/(TR – SR)] x 100, where ER 
(experimental release) is number of  Sytox positive cells in wells with soluble proteins, 
SR (spontaneous release) from wells containing untreated NK cells, and TR (total release) 
from wells containing NK cells and 1% Triton X-100 non-ionic surfactant (Sigma 
Aldrich).   
 
2.10 Statistical Analysis 
Experimental values were expressed either as mean + SD. Data was analyzed using the 
Student’s t-test for paired values, and one- and two-way ANOVA with a Bonferonni post-
hoc corrections test.  
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Chapter 3  
3 RESULTS 
 
3.1 TEC Clr-b expression is increased in vitro following 
stimulation with IFN- and TNF- 
Our previous work has demonstrated that NK cells can directly mediate TEC death 
in vitro, and that NK cells are important participants in an in vivo model of K-IRI (41). We 
have also demonstrated TEC apoptosis and increased expression of Fas receptor can be 
induced by IFN-, a pro-inflammatory cytokine secreted by activated NK cells (75, 104). 
This finding suggests NK cells may indirectly induce TEC death in addition to initiating 
direct contact-dependent cytotoxicity. To date, the role of Clr-based, MHC-1 independent 
inhibition of NK cells by TEC has not been investigated.  
To investigate the interaction between TEC expressing different levels of inhibitory 
Clrs and NK cells, we isolated primary TEC and NKs from both B6 mice. Primary NK 
cells were isolated from the spleens of B6 mice and cultured for at least seven days in the 
presence of human IL-2. Using a Nikon Eclipse 90i microscope, phase-contrast images of 
cultured NK cells were taken before and after stimulation with IL-2 (Figure 1A and 1B). 
IL-2-primed NK cells appeared larger in size with an aberrant morphology compared to 
untreated NKs (Figure 1A and 1B). Previous work from our lab has demonstrated that 
culturing NK cells with IL-2 greatly enhances their ability to kill TEC in vitro (41). We 
isolated primary TEC from the kidneys of mice and cultured these cells in full K1+/+ media 
prior to experiments. Our TEC displayed a cobblestone morphology that is consistent 
previously published TEC morphology analysis (Figure 2A) (105, 106).  
We tested whether TEC might attempt to limit NK injury in an inflammatory 
environment as found in IRI, by increasing surface expression of inhibitory Clr-b and Clr-
f. We treated primary TEC in vitro with sublethal amounts of pro-inflammatory cytokines 
TNF𝛼 and IFN𝛾 for 24 hrs. RNA was isolated from both treated and untreated TEC, cDNA 
was generated, and fold change of expression of Clr-b and Clr-f was quantified using qPCR. 
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Interestingly, only expression of Clr-b was significantly increased following treatment with 
proinflammatory cytokines, while Clr-f did not display a consistent increase in expression 
(Figure 2B). Previous unpublished work from our lab has also demonstrated that kidney 
mRNA and protein expression of Clr-b increases in a time-dependent manner in an in vivo 
model of IRI. Thus, we believe that TEC increase expression of Clr-b in an attempt to 
protect themselves from NK-mediated cytotoxicity.  
 
 
 
 
 
 
 
 
 
 
18 
 
 
Figure 1. NK cell before and after IL-2 priming.  
Splenocytes labeled with biotin-conjugated CD3ε primary antibodies and an anti-biotin 
magnetic MACS bead were passed through a magnetic MACS bead column to deplete 
CD3ε+ cells. NK cells were then purified from the flow through by CD49b+ selection on 
MACS beads column using anti-CD49b magnetic MACS beads. NK cells were cultured 
with human IL-2 for 7 days (Day1 - 2000 IU/mL, Day 3 – 1500 IU/mL). Images were 
captured at a 100X magnification (A) before treatment with IL-2 and (B) after 7 days of 
treatment. NK cells show a typical change in shape with activation. 
 
 
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
A. 
  
B. 
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(A) Tubular epithelial cells (TEC) were isolated from mouse kidneys after digestion with 
collagenase. A stitched image (left) and single image (right) were captured at 20X 
magnification using differential Interference microscopy (DIC). (B) Primary TEC were 
treated in vitro for 24 hrs with 25ng/mL of IFN𝛾 and 25ng/mL of TNF𝛼 in full K1+/+ media. 
RNA was isolated from cultured cells and cDNA was generated. Relative fold change of 
Clr-b and Clr-f mRNA expression by primary TEC before and after cytokine treatment was 
determined by qPCR. Data is shown as Mean + SD (Clr-b; n=4, Clr-f n=6). **p<0.01, 
Student’s t-test for paired values.   
 
A. 
B. 
Figure 2. TEC Clr-b expression is increased in vitro following stimulation with IFNγ 
and TNFα. 
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3.2 Inhibition of Clr-b and Clr-f expression in C57BL/6 
primary TEC 
To study the possible inhibitory effects of Clr-b and Clr-f expressed by TEC, we 
sought to observe any changes in the magnitude of NK cell-mediated killing in against TEC 
deficient in these proteins. Dr. Matthew Gillespie from the University of Monash, Australia 
generously provided our group with Clr-b-/- (Ocil-/-) B6 knockout mice. The Clr-b-/- B6 
mice have a targeted deletion of exon-3 in the Clec2d gene, resulting in a frameshifted 
transcript, and a non-functional ectodomain (107). Both WT and Clr-b-/- transcripts were 
detected using PCR, however the mutated transcripts were smaller than WT, confirming 
the deletion of exon-3 and the genotype of our Clr-b-/- mice (Figure 3A). 
To inhibit expression of Clr-f, we utilized siRNA to silence Clr-f mRNA transcripts 
in both WT and Clr-b-/- B6 primary TEC in vitro. Using a GFP fluorescent siRNA and live-
cell imaging analysis, we confirmed a high efficiency of transfection in cultured primary 
TEC, indicating siRNA would be suitable method for manipulating protein expression of 
Clr-f (Figure 3B). We designed siRNA for Clr–f that targeted exon-5 of the mRNA 
transcript and created primers to detect decrease in transcript via qPCR. A visualization of 
this design was created using SnapGene (Figure 3C). Using both vehicle and scrambled 
siRNA controls, we successfully silenced Clr-f transcripts at 24, 48, and 72 hrs (Figure 3D). 
Despite extensive searching, no functional anti-mouse Clr-f antibody for the purposes of 
confirming a decrease in protein levels of Clr-f via western blot or flow cytometry could 
be procured.  
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A. 
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A. 
C. 
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TEC were isolated from the kidney of WT B6 mice and transfected with siRNA. (A) PCR 
analysis of Clr-b transcript expression using primers specific for exons-2 through -4 for the 
coding sequence of Clr-b. The smaller band observed in the Clr-b-/- (Ocil-/-) mice is 
indicative of deletion of exon-3 of the Clr-b transcript, rendering the ectodomain of the 
protein non-functional. (B) A scrambled fluorescent siRNA control was used to confirm 
transfection efficiency. Image was taken using an IncuCyte Live-Cell Imager at 4x 
magnification. (C) Visual representation of Clr-f siRNA that targets exon-5 and the primers 
used in qPCR to confirm transcript silence. (D) TEC were transfected with siRNA that 
targets the transcripts for Clr-f. RNA was isolated using Trizol at different time points, 
converted into cDNA and qPCR was performed to compare the relative fold of expression 
change compared to a vehicle control at each time point. Data at each time point were 
shown as mean + SD (n=4). *p<0.05, **p<0.01, 2-way ANOVA.   
 
 
 
Figure 3. Inhibition of Clr-b and Clr-f expression in C57BL/6 primary TEC. 
D. 
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3.3 Inhibition of both Clr-b and Clr-f, but neither protein 
individually, significantly increases NK cell-mediated 
TEC killing. 
NK cell-mediated TEC death was measured at three different NK:TEC ratios in co-
culture using a standard 51Chromium (51Cr)  Release Assay as described in Materials and 
Methods. Forty-eight hours prior to co-culture with NKs, primary TEC from WT and Clr-
b-/- kidneys were either silenced with Clr-f siRNA or treated with transfection reagent alone 
as a vehicle control. All cells were isolated from a B6 background to control for the primary 
NK cell inhibitory molecule MHC class-1. The inhibition of either Clr-b or Clr-f expression 
on TEC did not significantly increase NK cell-mediated killing (Figure 4A). However, at 
a ratio of 30:1 NK:TEC, the simultaneous absence of both Clr-b and Clr-f expression 
resulted in significantly increased NK killing of TEC compared to the Clr-b-/- , Clr-f 
silenced, or WT control TEC groups (Figure 4A).  
To further demonstrate that absence of the signal from both Clr-b and Clr-f is 
sufficient to illicit the observed increase in NK cell-mediated killing, we co-cultured TEC 
deficient in one or both inhibitory Clrs with NK cells from either WT or Clr-b-/- mice. As 
NK cells from Clr-b-/- B6 mice have not developed in the presence of Clr-b, we 
hypothesized that these NK cells would not possess fully competent NKR-P1B receptors. 
At a ratio of 30:1 NK:TEC, there is no significant difference in Clr-b-/- TEC death between 
WT and Clr-b-/- NK cell groups (Figure 4B). This result was consistent with our previous 
observation there appears to be no significant difference in NK cell-mediated killing 
against TEC when Clr-b alone is absent compared to WT TEC (Figure 4A). However, Clr-
b/f -/- TEC were killed significantly more when co-cultured with WT NK cells compared 
to the same TEC co-cultured with NK cells from Clr-b-/- mice (Figure 4B).  
It is our hypothesis that NKR-P1B on Clr-b-/- NK cells are functionally tolerant to 
Clr-b-/- targets, and therefore cannot sense the absence of Clr-b on Clr-b/f -/- TEC. As no 
loss of inhibitory signal is detected, the NK cells do no initiate increased cytotoxicity 
against the Clr-b/f -/- TEC. Instead, we report a decrease in the magnitude of TEC death 
that is more consistent with groups lacking a single inhibitory Clr protein, like the Clr-f 
silence group from Figure 4A. We conclude that inhibition of both Clr-b and Clr-f protein 
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expression, but neither protein individually, is sufficient to significantly increases NK cell-
mediated TEC killing.  
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(A) NK cell-induced cell death was compared between TEC expressing different levels of 
Clr-b and Clr-f. SiRNA-mediated Clr-f silencing was performed 48 hrs prior to the cell 
death assay. TEC were labelled with 51Cr and co-cultured for 4 hrs at 37˚C, 5% CO2. Free 
51Cr in 100µL of supernatant from each well was counted and percent death was calculated 
using spontaneous and total 51Cr release controls. Each group was plated in duplicate for 
each ratio. Values are presented as mean + SD (n=3-4), *p<0.05, ***p<0.001, 2-way 
ANOVA, Bonferonni corrections test. (B) 51Cr labelled TEC deficient in one or both 
inhibitory Clrs were co-cultured for 4 hrs (37˚C, 5% CO2) with NK cells from either WT 
A. 
Figure 4. Elimination of both Clr-b and Clr-f, but neither protein individually, 
significantly increases NK cell-mediated TEC killing. 
B. 
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or Clr-b-/- mice. Percent cell death was calculated as described above. Each group was 
plated in duplicate for each ratio. Values are presented as mean + SD (n=5-6), *p<0.05, 
**p<0.01, 2-way ANOVA, Bonferonni corrections test. 
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3.4 A combination of soluble Clr-b and Clr-f reduces NK-
mediated killing of TEC in vitro 
As NK cells are not explicitly targeted with immunosuppressants in kidney 
transplantation and IRI, we tested whether soluble versions of Clr-b and Clr-f could reduce 
injury by an effect on NK cytotoxicity. Using sequence information from Uniprot (Clr-b: 
Entry #Q91V08; Clr-f: Entry #Q8C1T8), we expressed soluble forms of 6X His-tagged 
Clr-b (sClr-b) and Clr-f (sClr-f) ectopic domains in tobacco plants, a system which allows 
transient and high efficiency production of proteins of interest, that is free of endotoxin. 
Proteins were extracted and purified from leaf mass. We confirmed expected size of our 
sClrs using a Western blot: ~20kD and ~18kD for sClr-b and sClr-f respectively (Figure 
5A and B). This work was done in collaboration with Dr. Shengwu Ma of Lawson Health 
Research Institute. 
GAD65 is a membrane associated enzyme that catalyzes the decarboxylation of 
glutamate to GABA and CO2 (108). Human GAD65 would not be expected to interact with 
murine NK cells, thus serving as a useful control. Human recombinant GAD65 (hGAD65) 
was generated with the same method as sClr-b and sClr-f, and used as a soluble protein 
control in assays. NK cells were cultured in a wide range of concentrations of soluble Clr 
proteins to define concentrations that could contribute to any direct effect on NK viability. 
This was essential to exclude sClr-induced NK cell death as a confounding variable in our 
assessment of the capacity of sClr-b and sClr-f to protect TEC from NK-mediated 
cytotoxicity. Percent NK cell death after 4 hrs of culture was quantified by flow cytometry 
and defined as propidium iodide positive cells (Figure 5C), and by live-cell imaging 
(Figure 5D). Compared to PBS vehicle controls, 80ng/mL of each sClr-b and sClr-f did not 
induce NK cell death (Figure 5C). However, compared to vehicle and hGAD65 controls, 
much higher (240ng/mL and 400ng/mL) concentrations of soluble sClr could reduce NK 
viability (by 16% and 21% of NK cells respectively) (Figure 5C). Therefore, all assays 
were conducted using 80ng/mL to treat NK cells in co-culture experiments.  
To investigate if soluble Clr proteins possessed any capacity to inhibit NK cells, we 
treated NK cells with Clr proteins and co-cultured these cells with either WT or Clr-b/f 
deficient TEC. Thirty minutes prior to co-culture, hGAD65, sClr-b, sClr-f, or both sClrs 
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were added to wells containing only NK cells. TEC were labelled with 51Cr and co-cultured 
with treated or untreated NK cells for 4 hrs. Interestingly, only NK cells treated with both 
soluble Clrs killed significantly less Clr-b/-f -/- TEC than untreated NK cells (Figure 5D). 
As expected, hGAD65 soluble protein control did not significantly affect NK cell-mediated 
TEC killing (Figure 5D). Notably, our results suggest that treatment with sClr-f alone might 
attenuate NK cell activation, however this trend did not achieve statistical significance 
(Figure 5E).  
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Soluble forms of 6X His-tagged (A) Clr-b (sClr-b) and (B) Clr-f (sClr-f) were generated. 
Purification was performed on a Nickel affinity chromatography column, and molecular 
weight was confirmed via western blot.  NK cell viability was tested after 4 hrs of culture 
with selected concentrations of our soluble proteins. hGAD65, a protein not predicted to 
interact with NK cells, was generated and purified with the same method as the sClrs, and 
was used as a soluble protein control for our system. (C) Percent cell death was quantified 
by flow cytometry and defined as propidium iodide positive NK cells (n=1). (D) NK cell 
viability was also measured kinetically over a 4 hr time period using an IncuCyte live 
C. 
D. 
Figure 5. A combination of soluble Clr-b and Clr-f reduces NK-mediated killing of 
TEC in vitro. 
E. 
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cell fluorescent imaging machine. Data is shown as mean of wells plated in triplicate for a 
single experiment. (E) To investigate if our soluble proteins possessed the capacity to 
inhibit NK cells, we treated NK cells with our proteins and co-cultured these cells with 
either WT or Clr-b/f deficient TEC. Thirty minutes prior to co-culture, 250ng/mL of soluble 
hGAD65, 80ng/mL of sClr-b, 80ng/mL of sClr-f, or 80ng/mL of both sClrs was added to 
wells containing only NK cells. TEC were labelled with 51Cr and co-cultured with treated 
or untreated NK cells for 4 hrs at 37˚C, 5% CO2. Each group was plated in triplicate for 
each ratio. Values are presented as mean + SD (n=5-6), *p<0.05, 1-way ANOVA. 
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4 DISCUSSION 
 
4.1 Regulation of NKR-P1:Clr Recognition System during 
IRI 
The augmented killing of TEC in vitro following loss of Clr-b and Clr-f strongly 
supports that NKR-P1:Clr binding is an important inhibitory pathway in NK-mediated 
kidney injury. A central question remains: given that NK cells have a wide spectrum of 
receptors with which they interact, what purpose does Clr expression serve by targeted 
cells in vivo? It has been demonstrated that Clr-b exhibits broad expression across many 
tissues and hematopoietic cells (97). As Clr-f exhibits a highly specific tissue expression 
pattern restricted to the kidney, liver, and intestinal tract in B6 mice, it is likely that Clr-f 
serves a non-redundant function to Clr-b. We treated TEC in vitro with IFN- and TNF- 
(Figure 2B), two potent pro-inflammatory cytokines that are both expressed in large 
quantities in the kidney during IRI. While Clr-b was significantly upregulated by this 
treatment, it remains unknown whether this represents an endogenous mechanism by which 
TEC decrease their susceptibility to NK cell cytotoxicity or a general upregulation of 
surface receptors found during inflammation. Unlike Clr-b, “inhibitory” Clr-f was not 
consistently upregulated by pro-inflammatory cytokine treatment in TEC (Figure 2B). 
While Clr-f may not be induced by IFNγ in TEC, previous studies have provided insight 
into the regulation of Clr-f. Steinle et al. have reported enhanced Clr-f expression on the 
surface of BALB/c mouse intestinal epithelial cells (IECs) ex vivo sixteen hours following 
intraperitoneal injection with poly(I:C), a synthetic analogue of double-stranded RNA 
(103). Interestingly, the challenge with poly(I:C) also corresponded with a decreased 
frequency of NKR-P1G+ intraepithelial lymphocytes (IELs) and NKR-P1G protein 
expression on IELs (103). It is plausible that IELs and NK cells downregulate expression 
of NKR-P1G in the presence of poly(I:C) to decrease their ability to respond to inhibitory 
signals from Clr-f, so that they may more efficiently clear viral infection. Poly(I:C) is a 
ligand for toll-like receptor 3 (TLR3) which is expressed by splenic murine and human NK 
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cells (109). Upon simultaneous culture with poly(I:C)  and suboptimal doses of IL-12, 
human NK cells become capable of producing IFN- and TNF-, express high levels of 
activating markers CD69 and CD25, and acquire cytolytic activity against immature 
dendritic cells (iDCs) (110). Given that expression of activating markers is increased 
following TLR3 stimulation, a simultaneous decrease in inhibitory receptors is consistent 
with enhanced viral clearance.  
TLR3 stimulation during IRI may decrease expression of NKR-P1G on infiltrating 
NK cells, while simultaneously promoting NK cell production of IFN- and TNF-. While 
our data seems to indicate that the absence of inhibitory Clr-f:NKR-P1G signalling alone 
is insufficient to significantly increase NK killing of TEC in vitro (Figure 4A), the 
inflammatory in vivo environment of kidney IRI may tip the scales in favor of NK cells 
initiating direct cytotoxicity against TEC. Interestingly, TLR3-mediated induction of NK 
cell IFN- release would increase the expression of Clr-b by TEC. We have previously 
demonstrated that kidney Clr-b is increased in a time-dependent manner following an in 
vivo model of IRI (111). NK cells may therefore initiate direct toxicity against TEC during 
IRI due to stimulation by NKG2D ligands like Rae-1 and absence of Clr-f:NKR-P1G-
mediated inhibition, despite sufficient levels of Clr-b expression. Thus, restoring the 
inhibitory signal from Clr-f by preventing possible TLR3-mediated downregulation of 
NKR-P1G may prove to be an effective therapy for reducing acute kidney from NK cell 
activation. 
 
4.2 NKR-P1B/G signaling during engagement with TEC Clr-
b/-f 
 To study the possible inhibitory effects of Clr-b and Clr-f expressed by TEC on 
NK function, we assessed NK cell-mediated killing against TEC deficient in these proteins. 
Elimination of either Clr-b or Clr-f expression on TEC did not significantly increase NK 
cell-mediated killing (Figure 4A). However, combined loss of both Clr-b and Clr-f 
expression resulted in significantly increased NK killing of TEC (Figure 4A). The 
mechanism by which loss of Clr expression enhances NK killing has not been elucidated. 
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One possibility is that increased killing of TEC occurs at the level of the NK:TEC lytic 
synapse. Following cell-to-cell contact, firm adhesion is mediated by the integrin family of 
adhesion molecules, and inhibitory/stimulatory NK receptors cluster at the synapse (112). 
Whether an NK cell proceeds to actin reorganization and cytotoxic degranulation seems to 
depend on the presence or absence of sufficient inhibitory signalling from the target cell 
(113). Our data suggest that elimination of both Clr-b and Clr-f, but neither protein 
individually, is sufficient to override inhibition from MHC class-1, and induce significant 
direct NK activation against TEC.  
TEC deficient in both Clr-b and Clr-f were more susceptible to death when co-
cultured with WT NK cells compared with NK cells from Clr-b-/- mice (Figure 4B). As NK 
cells from Clr-b-/- B6 mice have not developed in the presence of Clr-b, we considered 
whether this was an impairment related to NKR-P1B not being a fully competent receptor 
on Clr-b-/- NK cells. The concept of NK receptor education and NK cell licensing has 
support other models of NK activation. For example, NK cells from MHC class-1-deficient 
(β2M-/-) mice demonstrate poor killing of MHC class-1-deficient targets even though are 
unchanged in number, tissue distribution, and expression of activating receptors (114, 115). 
WT B6 NK cells readily produced IFNγ upon crosslinking of the activating NK1.1 
receptor, however NK cells derived from β2M-/- mice produce almost no IFNγ following 
NK1.1 stimulation (116). This observation seems to indicate NK cells from β2M-/- mice are 
functionally defective, and that education through MHC class-1 is required to achieve the 
functional competence of NK cells (117). NK cells developed in an irradiated chimeric B6 
β2M-/- mouse model reconstituted with WT B6 bone marrow (BM) cells were compromised 
in their ability to subsequently reject β2M-/- BM (118). Conversely, such “unlicensed” 
mature MHC class-1-deficient splenic NK cells show a gain of function and acquire a 
licensed phenotype after adoptive transfer in wild type hosts (119). These cells produce 
IFNγ at the same level as WT NK cells, and gain equivalent ability to degranulate as 
indicated by CD107a staining (119). Clearly, MHC class-1 engagement during NK cell 
development is necessary to produce functional NK cells. As NKR-P1B serves a similar 
function to receptors that recognize MHC class-1, it is similarly possible that interaction 
with Clr-b, possibly during development, is a requisite for fully competent NK cells. Such 
data also highlights the complex biology of NK cells and that interaction with Clr proteins 
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at sites distant to the eventual target tissue can have a profound effect on NK function. 
Interestingly, NK cells that do not express functional inhibitory receptors for MHC 
class-1 are not autoreactive but rather are hyporesponsive against β2M-/- targets (120). 
Work by Chen et al. has demonstrated that while NK cells from Clr-b-/- mice are 
hyporesponsive to NK1.1 stimulation and IL-12/IL-18 cytokine priming, the inhibitory 
capacity of the NKR-P1B receptor remains intact (121). We observed that combined Clr-
b/-f-deficient TEC were killed significantly more when co-cultured with WT NK cells as 
compared with NK cells from Clr-b-/- mice (Figure 4B). Despite NKR-P1B on Clr-b-/- NK 
cells possessing a capacity to be inhibited by the Clr-b protein, it appears that these NKs 
are “tolerant” to Clr-b-/- targets. Clr-b-/- NK cells do no initiate increased cytotoxicity 
against TEC lacking Clr-b/-f expression, highlighting that change in signalling from a 
single inhibitory Clr protein is not sufficient to affect NK cell activation against TEC. Our 
findings provide further evidence that the NKR-P1B receptor must interact with its cognate 
ligand Clr-b at some point, in order to efficiently sense a decrease of Clr-b expression, and 
then augment NK cell-mediated killing of target cells.  
 
4.3 Soluble Clr-b/-f as a new K-IRI therapeutic 
Following our demonstration of enhanced NK killing of TEC in the absence of 
surface expression of Clr-b and -f in vitro, we sought to determine whether our 
understanding of NK regulation by TEC via Clr proteins could be exploited to decrease 
TEC death during IRI. As the different forms of Clr proteins are highly similar, antibodies 
meant to bind inhibitory NKR-P1 receptors in vivo may induce undesirable agonist effects 
by binding to and stimulating NKR receptors. Alternatively, genetic alteration to increase 
the expression of Clr-b/-f in kidneys could induce NK cell hyporesponsiveness and loss of 
viral clearance. It was demonstrated that sustained transgenic expression of NKG2D 
ligands Rae-1 in mice results in reduced expression of NKG2D and impairment of 
NKG2D-mediated NK cell activation (122). In the same manner, systemic transgenic 
overexpression of Clr-b/-f may cause a downregulation of NKR-P1B/G receptors in vivo. 
Therefore, we created soluble forms of the ectopic domains of Clr-b and Clr-f. Drug 
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delivery of additional Clr-b and Clr-f molecules may clinically feasible to promote the 
inhibitory potential of these molecules against NK cells. The ability of such soluble Clr 
proteins to inhibit NK cells may be related to perturbation of the NK-TEC synapse, or by 
inhibition of NK cell activation capacity even prior to engagement with target cells. This 
remains for future studies. 
We repeated NK:TEC co-culture experiment comparing the cytotoxicity of sClr-
b/-f treated and untreated NK cells. Of note, the concentrations of Clr proteins added to 
assays were approximated as no standards are currently available for precise 
determinations. Thus, we used total protein levels obtained in affinity purified eluates. 
While sClr-b and sClr-f appear to be toxic to NK cells when combined at very high 
concentrations of each Clr (240 and 400ng/mL of each) (Figure 5C), concentrations of 
80ng/mL did not induce NK cell death as compared to vehicle and soluble protein controls. 
Similarly, in a previous experiment by Zhou et al., a recombinant murine OCIL (Clr-b) 
protein significantly inhibited osteoclast formation in vitro at a concentration of 50ng/mL 
(123).  Our results provide guidance into concentrations that might be required for effective 
in vitro treatment with soluble Clrs. NK cells treated with a combination of sClr-b and sClr-
f  killed significantly less Clr-b/-f -/- TEC than untreated NK cells (Figure 5D). Interestingly, 
treatment with sClr-f alone appeared to reduce NK cell killing of TEC. However statistical 
significance was not achieved, but perhaps optimization of the model would have clarified 
its effects more definitely (Figure 5D). Future experiments from our group will seek to 
further demonstrate the capabilities of sClr-f in protecting transformed targets with 
compromised MHC class-1. Additionally, we will investigate the potential for sClr-b/-f to 
protect from NK cell-mediated injury during IRI, using an in vivo mouse model of kidney 
IRI. 
Interestingly, the NKR-P1A receptor in humans, thought to be a homologue of 
NKR-P1B in mice, is expressed across a wide variety of immune cell types including NK 
cells,  and  T cells, mucosal associated invariant T (MAIT) cells, invariant CD1d 
specific NKT cells, Th17 cells, Tc17 cells, and CD4+CD25highFoxP3+ regulatory T cells 
(124–131). While NKR-P1A ligation with its ligand LLT1 is reported to be inhibitory in 
NK cells, many studies have demonstrated a co-stimulatory function of NKR-P1A ligation 
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in T cells (94, 125, 132–135). As NKR-P1A in humans appears to possess opposing anti-
inflammatory/pro-inflammatory functions depending on the cell type it is expressed on, 
future studies will need to carefully examine the side effects of using a NKR-P1 agonist 
such as soluble Clr-b/-f or soluble LLT1 to inhibit NK cells.  
 
4.4 Consequences of Genetic Variability for IRI Severity 
In human kidney transplant patients, there is a substantial amount of variability in 
the severity of delayed graft function (DGF) and acute kidney injury (AKI). DGF following 
transplant is thought to be primarily a consequence of IRI (136). Factors such as donor age 
and genetic factors have been implicated in the severity of injury (137, 138).We do not, 
however, have a comprehensive database on the specific genomic characteristic of donors 
and recipients, and how genetic variation in donor organs may impact transplant outcomes. 
For example, inter-individual variations exists in many of the genes that regulate cytokine 
and chemokine expression, and this is being increasingly recognized as an important 
variable in allograft outcomes (139). Hutchinson et al. has correlated a G308A 
polymorphism in the recipients TNFα promoter region with an increased rate of rejection 
and an increased rate of steroid-resistant rejection in kidney transplant recipients (140, 141) 
Hoffmann et al. demonstrated that donor TGF-β haplotypes associated with increased 
protein production are associated with a development of acute cellular rejection in 
transplanted grafts (139). Similarly, genetic variation in the expression of inhibitory 
molecules Clr-b/-f, or NK receptors NKR-P1B/G may likely have an impact on IRI 
severity. Carlyle et al. have reported a high degree of divergence observed for the NKR-
P1B/D alleles between the 129S1/BALB/c and B6 mouse strains (84). Notably, the NKR-
P1B129 receptor appears to respond more robustly than NKR-P1BB6 to titrated doses of 
239T Clr-b stimulator cells (142). The 129S1 and BALB/c NKR-P1G allele are identical, 
yet both differ from the B6 allele by a single nucleotide resulting in an amino acid 
substitution (143). Similarly, 129S1 and BALB/c Clr-f alleles are identical, but differ B6 
by three amino acid substitutions (143). Our group has previously demonstrated that B6 
mice are more susceptible than BALB/c mice to glomerular necrosis, decreased kidney 
function, and tubular cell death following IRI (111). It may be possible that polymorphisms 
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in the NKR-P1:Clr recognition system confer decrease susceptibility to IRI in B6 mice.  
Consequently, variations in the homologue human NKR-P1:LLT1 recognition 
system may account for some of the DGF and IRI variability observed between patients. 
A study done by Rother et al. demonstrated that a c.503T>C SNP results in an amino acid 
transversion (Ile168Thr) in the extracellular domain of the NKR-P1A (CD161) receptor 
which is involved in the binding of LLT1 (144). This mutation resulted in diminished 
binding of LLT1 to NKR-P1A, and ligation of the mutated NKR-P1A receptor with LLT1 
or anti-NKR-P1A antibodies inhibited NK cell activation to a lesser degree as defined by 
CD107 staining (144). Future studies no doubt will assess for potential genetic variability 
in genes coding for human NKR-P1/LLT1 proteins in DGF and non-DGF patients.  
 
4.5 Conclusions 
The Clr family of proteins and their ligands represent a highly complex and 
conserved mechanism by which NK cells can interact with diverse cell types, leading to 
inhibition and dampening of inflammation, or activation with potent destruction. While 
these receptors likely evolved to be yet another process by which hosts deal with ‘danger’ 
presented by cancer and infection, NK cells and their receptor interactions create a 
formidable challenge in organ transplantation. TEC may increase their expression of Clr-b 
with ischemia-reperfusion renal injury as an attempted mechanism for self-protection from 
overactive NK cells during inflammation. The augmented killing of TEC in vitro following 
loss of Clr-b and Clr-f strongly supports that NKR-P1:Clr binding is an important inhibitory 
pathway in NK mediated kidney injury. No current drugs target NK cells during acute 
kidney injury or following transplantation. Therefore, greater knowledge is required to 
generate novel strategies to block NK participation in IRI for example. In our work, we 
have demonstrated that manipulation of Clr-b and Clr-f expression can alter TEC injury.  
Alternatively, as alteration of organ expression of any protein presents considerable 
challenges, we have demonstrated that soluble Clr proteins that bind to NK cells bearing 
NKR-P1 receptors can alter their cytotoxic capacity and thus may represent a clinically 
feasible strategy to protect organs from diverse forms of NK cell-mediated inflammation 
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and injury. Future detailed work is required to expand on the findings presented here.  
 
4.6 Future Directions 
Now that we have provided some evidence for the inhibitory capabilities of a Clr-
b/-f soluble protein combined treatment, we will use a previously established in vivo model 
of mouse kidney IRI to investigate the capacity of these proteins to protect mice from 
kidney injury during ischemia-reperfusion.  
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